Immunology
The Inflammasome
Cytosolic danger sensor — NLRP3, ASC, caspase-1, IL-1β and pyroptosis
The inflammasome is a cytosolic multiprotein complex that senses infection and cellular damage and converts that signal into inflammation. A sensor protein — most famously NLRP3, but also NLRP1, NLRC4, AIM2, and Pyrin — detects pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs), then nucleates the adaptor ASC into a single micron-scale speck that clusters and activates pro-caspase-1. Active caspase-1 matures interleukin-1β and interleukin-18 and cleaves gasdermin D, whose pore ruptures the cell in the lytic death called pyroptosis. NLRP3 was cloned in 2001 by Hal Hoffman and colleagues as the gene mutated in cryopyrin-associated periodic syndromes, and Fabio Martinon, Kimberly Burns, and Jürg Tschopp coined the term "inflammasome" in 2002. The pathway underlies gout, silicosis, atherosclerosis, and monogenic autoinflammatory disease, and is targeted clinically by anakinra, canakinumab, and the experimental NLRP3 inhibitor MCC950.
- NamedMartinon, Burns, Tschopp 2002
- Core partssensor + ASC + caspase-1
- Output cytokinesIL-1β & IL-18
- Executioner poregasdermin D (~10–20 nm)
- Cell deathpyroptosis (lytic)
- Diseasesgout, CAPS, atherosclerosis
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
Why the inflammasome matters
- It is the master switch for IL-1β. Interleukin-1β is one of the most potent pyrogens known — nanogram quantities produce fever, and it drives neutrophil recruitment, endothelial activation, and the acute-phase response. Unlike most cytokines, it is made as an inactive precursor with no signal peptide and cannot leave the cell until caspase-1 both cleaves it and opens a gasdermin D pore. The inflammasome is that gate.
- It explains sterile inflammation. Gout, pseudogout, silicosis, asbestosis, and the plaque inflammation of atherosclerosis are all driven by NLRP3 sensing particulates — monosodium urate, calcium pyrophosphate, silica, asbestos fibers, and cholesterol crystals respectively. No microbe is involved; the danger signal is a crystal that ruptures the phagolysosome.
- It defines a whole disease class. Autoinflammatory diseases — as opposed to autoimmune ones — arise from unrestrained innate immunity. Gain-of-function NLRP3 mutations cause the cryopyrin-associated periodic syndromes (CAPS), and MEFV mutations in Pyrin cause familial Mediterranean fever. These patients taught immunologists that spontaneous fever can be a channelopathy of danger sensing.
- It is a validated drug target. IL-1 blockade with anakinra (IL-1 receptor antagonist), canakinumab (anti-IL-1β antibody), and rilonacept (IL-1 trap) can abolish CAPS symptoms within hours. The CANTOS trial (2017, ~10,000 patients) showed canakinumab cut recurrent cardiovascular events, the first clinical proof that lowering inflammation independent of cholesterol reduces heart attacks.
- It is a first-line antimicrobial sensor. NLRC4 detects the bacterial flagellin and type-III secretion rod of Salmonella, Legionella, and Pseudomonas; AIM2 detects cytosolic double-stranded DNA from viruses and Francisella. Pyroptosis of an infected macrophage denies intracellular bacteria their replicative niche and exposes them to neutrophils.
- It links metabolism to immunity. NLRP3 responds to metabolic danger — cholesterol crystals, islet amyloid polypeptide, ceramides, and excess glucose — placing the inflammasome at the center of type 2 diabetes, obesity, and cardiovascular disease, where chronic low-grade IL-1β signaling damages tissue over decades.
How the inflammasome works
Inflammasome assembly is a nucleated polymerization triggered by two signals. Signal 1 (priming) is transcriptional: a pattern-recognition receptor such as a Toll-like receptor, or a cytokine like TNF, activates NF-κB, which raises cellular levels of the sensor (NLRP3) and of pro-IL-1β. In a resting cell these proteins are scarce, so priming is a prerequisite. Priming also delivers non-transcriptional licensing — deubiquitination and phosphorylation events that ready NLRP3 for assembly within minutes.
Signal 2 (activation) is delivered by an extraordinarily diverse set of stimuli: extracellular ATP acting through the P2X7 channel, the pore-forming toxin nigericin, and phagocytosed particulates including monosodium urate, silica, asbestos, and cholesterol crystals. Because no single molecule binds all of these, NLRP3 is thought to detect a shared downstream perturbation — cytosolic potassium efflux that drops K+ below roughly 90 mM, along with lysosomal destabilization, mitochondrial reactive oxygen species, and dispersal of the trans-Golgi network. The mitotic kinase NEK7 then bridges adjacent NLRP3 subunits, licensing them to oligomerize through their central NACHT (NOD) domains into a wheel-like disc.
Oligomerized NLRP3 exposes clustered pyrin domains (PYD), which template the adaptor ASC (PYCARD) to polymerize: ASC's PYD stacks into a helical filament, and its CARD domains project outward. The filaments condense into a single perinuclear ASC speck, roughly 1 μm across and visible by light microscopy — one per cell, an all-or-none commitment device. ASC's CARDs then recruit pro-caspase-1 through CARD–CARD interactions, forcing the proteases into proximity so they dimerize and autoprocess into active caspase-1.
Active caspase-1 has three principal substrates. It cleaves pro-IL-1β (31 kDa) and pro-IL-18 into their mature 17 kDa and 18 kDa cytokines. It cleaves gasdermin D between its N- and C-terminal domains; the liberated N-terminal fragment binds membrane phosphoinositides and cardiolipin and oligomerizes (about 16 subunits) into a ring-shaped pore roughly 10 to 20 nm in inner diameter. That pore both releases the leaderless IL-1 cytokines — which have no signal peptide for the classical secretory pathway — and admits water, so the cell swells and lyses in pyroptosis, spilling DAMPs that amplify the alarm. A parallel noncanonical pathway lets human caspase-4 and -5 (caspase-11 in mice) bind cytosolic bacterial lipopolysaccharide directly and cleave gasdermin D, triggering pyroptosis and, secondarily, K+ efflux that ignites NLRP3.
Common misconceptions
- "There is one inflammasome." Inflammasome is a family. Distinct sensors assemble distinct complexes: NLRP3 (broad danger), NLRP1 (proteolytic and toxin sensing), NLRC4 (bacterial flagellin/T3SS via NAIP proteins), AIM2 (cytosolic dsDNA), and Pyrin (RhoA-inactivating toxins). They share the logic — sensor, often ASC, caspase-1 — but detect very different threats.
- "The inflammasome fights only infection." Much of NLRP3 biology is sterile. Uric acid crystals in gout, cholesterol crystals in atheroma, and silica in the lung all activate NLRP3 with no pathogen present. The sensor reads danger, not foreignness.
- "IL-1β is secreted like a normal cytokine." Pro-IL-1β lacks a signal peptide and never enters the ER–Golgi secretory route. It exits through gasdermin D pores or upon pyroptotic lysis. This is why gasdermin D and cell death are so tightly coupled to IL-1 release.
- "NLRP3 directly binds ATP, urate, and silica." No shared ligand-binding pocket has been found. NLRP3 is an integrator that responds to common downstream events — potassium efflux, lysosomal rupture, mitochondrial ROS, Golgi dispersal — rather than a receptor for each stimulus.
- "Pyroptosis is just a messy version of apoptosis." They are mechanistically distinct programs with different caspases and opposite immunological intent. Apoptosis (caspases-3/7/8/9) is silent and packages debris for quiet clearance; pyroptosis (caspase-1/4/5/11 via gasdermin D) is lytic and deliberately inflammatory.
- "Caspase-1 is an apoptotic caspase." Caspase-1 was originally named ICE — interleukin-1β-converting enzyme — for its true job. It is an inflammatory caspase; its dominant substrates are pro-IL-1β, pro-IL-18, and gasdermin D, not the apoptotic executioner substrates cleaved by caspase-3.
Inflammasome (pyroptosis) vs apoptosis vs necroptosis
| Feature | Inflammasome / pyroptosis | Apoptosis | Necroptosis |
|---|---|---|---|
| Trigger | PAMPs/DAMPs sensed by NLRP3, AIM2, NLRC4 | BH3-only proteins, death receptors | TNF/TLR when caspase-8 is blocked |
| Key proteases/effectors | Caspase-1/4/5/11, gasdermin D | Caspases-3/7/8/9 | RIPK1, RIPK3, MLKL (no caspase) |
| Membrane fate | Gasdermin D pores, cell lyses | Intact, blebs into apoptotic bodies | MLKL pores, cell lyses |
| Inflammation | Very high — IL-1β, IL-18, DAMP release | Silent, anti-inflammatory | High (DAMP release) |
| Signature output | Mature IL-1β & IL-18, ASC speck | PARP cleavage, 180-bp DNA ladder | Phospho-MLKL at the membrane |
| Physiologic role | Danger alarm, antimicrobial defense | Development, homeostasis | Backup death when apoptosis fails |
| Drug target | NLRP3 (MCC950), IL-1 (anakinra, canakinumab) | BCL-2 (venetoclax) | RIPK1 (necrostatins) |
The inflammasome sensors compared
| Sensor | What it detects | Uses ASC? | Disease link |
|---|---|---|---|
| NLRP3 (cryopyrin) | K+ efflux, crystals, ATP, toxins, ROS — broad danger | Yes (obligate) | CAPS, gout, atherosclerosis, silicosis |
| NLRP1 | Proteolytic cleavage; anthrax lethal toxin, DPP9 loss | Partial (has own CARD) | Skin autoinflammation, MSPC |
| NLRC4 (via NAIPs) | Bacterial flagellin & type-III secretion apparatus | Partial (has own CARD) | NLRC4-MAS, enterocolitis |
| AIM2 | Cytosolic double-stranded DNA (viruses, bacteria) | Yes (obligate) | Antiviral defense, lupus links |
| Pyrin (MEFV) | Inactivation of RhoA by bacterial toxins | Yes (obligate) | Familial Mediterranean fever |
Famous experiments and history
- Martinon, Burns & Tschopp (2002). In Molecular Cell 10: 417–426 the Lausanne group described a caspase-1-activating complex containing NALP1 (NLRP1) and ASC and named it the "inflammasome." This paper defined the sensor–adaptor–caspase architecture that organizes the whole field.
- Hoffman et al. (2001). Positional cloning of CIAS1 (now NLRP3, encoding cryopyrin) in Nature Genetics identified it as the gene mutated in familial cold autoinflammatory syndrome and Muckle-Wells syndrome — the human genetics that later explained why these patients over-produce IL-1β.
- Martinon et al., gout (2006). In Nature 440: 237–241 Tschopp's group showed that monosodium urate and calcium pyrophosphate crystals activate the NLRP3 inflammasome to release IL-1β, giving gout and pseudogout a molecular mechanism and predicting the success of IL-1 blockade.
- Gasdermin D as the pyroptosis pore (2015). The groups of Feng Shao (Beijing) and Vishva Dixit (Genentech) independently identified gasdermin D as the caspase-1/-11 substrate whose N-terminal fragment forms the lytic membrane pore, converting caspase activity into pyroptotic death and IL-1 release.
- NEK7 as the licensing kinase (2016). Work in Nature showed NEK7 is required to bridge NLRP3 subunits for oligomerization, coupling inflammasome assembly to the cell cycle and revealing a druggable node upstream of ASC.
- CANTOS trial (2017). The Canakinumab Anti-inflammatory Thrombosis Outcome Study randomized roughly 10,000 post-MI patients to anti-IL-1β and showed reduced recurrent cardiovascular events independent of lipid lowering — clinical validation that inflammasome-driven IL-1β causes human atherosclerotic disease.
Frequently asked questions
What is the inflammasome and what does it do?
The inflammasome is a cytosolic multiprotein complex that acts as an alarm system of innate immunity. A sensor protein — NLRP3, NLRP1, NLRC4, AIM2, or Pyrin — detects pathogen-associated molecular patterns (PAMPs) such as bacterial flagellin or DNA, or danger-associated molecular patterns (DAMPs) such as extracellular ATP, uric acid crystals, or cholesterol crystals. On activation the sensor recruits the adaptor ASC, which polymerizes into a single micron-scale ASC speck. That speck clusters pro-caspase-1, forcing it to dimerize and autoactivate. Active caspase-1 then cleaves the inactive precursors pro-IL-1β and pro-IL-18 into mature, secreted cytokines and cleaves gasdermin D to open membrane pores. The result is a rapid, amplified inflammatory response — fever, neutrophil recruitment, and often the lytic cell death called pyroptosis.
How does the NLRP3 inflammasome get activated?
Canonical NLRP3 activation is a two-signal process. Signal 1 (priming) comes from a Toll-like receptor or cytokine receptor engaging NF-κB, which raises the levels of NLRP3 protein and pro-IL-1β — neither is abundant in a resting cell. Signal 2 (activation) is delivered by an enormously diverse set of stimuli: extracellular ATP acting on the P2X7 channel, pore-forming toxins like nigericin, and particulates such as monosodium urate crystals, silica, asbestos, and cholesterol crystals. Because no single ligand binds all of these, NLRP3 is thought to sense a common downstream perturbation — potassium efflux dropping cytosolic K+ below roughly 90 mM, plus lysosomal rupture, mitochondrial reactive oxygen species, and dispersal of the trans-Golgi network. NEK7 kinase then bridges adjacent NLRP3 molecules, licensing oligomerization and ASC nucleation.
What is the difference between the inflammasome and apoptosis?
Both are caspase-driven, but they use different caspases toward opposite ends. Apoptosis is silent, immunologically quiet cell death executed by caspases-3, -7, -8, and -9; the membrane stays intact, contents are packaged into apoptotic bodies, and phagocytes clear the debris without inflammation. The inflammasome uses inflammatory caspases — caspase-1 in the canonical pathway, caspase-4 and -5 in humans (caspase-11 in mice) in the noncanonical pathway. Its purpose is to broadcast danger: it matures IL-1β and IL-18 and cleaves gasdermin D, whose pore ruptures the cell in pyroptosis and spills alarm signals into the tissue. Apoptosis removes cells so quietly that neighbors never notice; pyroptosis does the opposite, converting one dying cell into a flare that summons the immune system.
What is pyroptosis and how does gasdermin D cause it?
Pyroptosis is a lytic, inflammatory form of programmed cell death triggered by inflammatory caspases. Active caspase-1 (or noncanonical caspase-4/-5/-11) cleaves gasdermin D between its N- and C-terminal domains, releasing the N-terminal fragment. Roughly 16 of these fragments oligomerize in the inner leaflet of the plasma membrane to form a ring-shaped pore about 10 to 20 nm in inner diameter — wide enough to pass mature IL-1β and IL-18, which lack signal peptides and cannot use the conventional secretory route. Water rushes in, the cell swells and ruptures, and it releases its cytoplasmic contents, including DAMPs, as a potent inflammatory signal. Gasdermin D was identified as the pyroptosis executioner in 2015 by the groups of Feng Shao and Vishva Dixit working independently.
How does the inflammasome cause gout?
Gout is a direct clinical demonstration of NLRP3 biology. When serum urate exceeds its solubility limit of about 6.8 mg/dL, monosodium urate (MSU) crystals precipitate in joints. Resident macrophages phagocytose the needle-shaped crystals, which damage the phagolysosome; the resulting lysosomal rupture and cathepsin release, together with potassium efflux, activate the NLRP3 inflammasome. Caspase-1 matures IL-1β, and the flood of IL-1β drives the excruciating, red-hot gouty flare by recruiting neutrophils. This mechanism, published by Martinon, Pétrilli, Mayor, Tardivel, and Tschopp in Nature in 2006, explained why colchicine works and predicted that IL-1 blockade would help: the IL-1 receptor antagonist anakinra and the anti-IL-1β antibody canakinumab both relieve flares refractory to standard therapy.
What are autoinflammatory diseases and how do they relate to the inflammasome?
Autoinflammatory diseases are caused by dysregulated innate immunity rather than the autoantibodies or self-reactive T cells of classical autoimmunity. Gain-of-function mutations in NLRP3 cause the cryopyrin-associated periodic syndromes (CAPS) — familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and the severe neonatal-onset NOMID/CINCA — producing constitutive IL-1β release, recurrent fevers, urticarial rash, and, in the worst forms, deafness and chronic meningitis. Mutations in MEFV, which encodes Pyrin, cause familial Mediterranean fever; mutations in NLRP1 and NLRC4 cause their own syndromes. The unifying signature is excess IL-1β, which is why IL-1-targeting biologics — anakinra, canakinumab, and rilonacept — are transformative treatments, often abolishing symptoms within hours to days.
Who discovered the inflammasome?
The term inflammasome was coined in 2002 by Fabio Martinon, Kimberly Burns, and Jürg Tschopp at the University of Lausanne, in a Molecular Cell paper describing a caspase-1-activating complex containing NALP1 (NLRP1) and ASC. The key sensor gene came a year earlier: in 2001 Hal Hoffman and colleagues positionally cloned CIAS1 — now NLRP3, encoding cryopyrin — as the gene mutated in familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Tschopp's lab then linked NLRP3 to gout crystals (2006) and cholesterol crystals in atherosclerosis, while ASC-speck imaging, the NEK7 requirement, and gasdermin D as the pyroptosis pore (Shao and Dixit, 2015) filled in the mechanism over the following decade.